2018 ASH meeting to feature new CAR-T therapies for myeloma
Bispecific antibodies like Amgen's AMG 420 could present some competition to CAR-Ts. But could sequential use of the therapies - which target the same antigen - be possible?
VelosBio raises $58M in Series A round for antibody-drug conjugate development
Arix Bioscience co-leads round with Sofinnova Ventures, investing $11 million and taking an 11.2 percent ownership stake in the San Diego-based firm.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.